Sanjay S. Shukla, M.D., M.S.

Sanjay S. Shukla, M.D., M.S.

President and CEOataTYR Pharma· In proxies 2022–2025

Pay in FY2025+133% from the year before · aTYR Pharma stock -78.4% the same year

Sanjay S. Shukla, M.D., M.S. was paid $3.5M in FY2025 (Dec), up 133%. aTYR Pharma stock fell 78.4% that year.

Pay$100 in the stock at the end of FY22 → $36
Pay is from the Summary Compensation Table of each aTYR Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. aTYR PharmaPublic company · 4 yr
    • President and CEO2022 – Present · 4 yrStock in role -98%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?